Clinical Trials

Clinical Trial
  • Status: Not yet recruiting
  • Phase: Phase 1
  • Intervention Type: Biological
  • Participants: 23
  • Start Date: July 12, 2021
Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 12
  • Start Date: May 3, 2021
Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia
Search for trials
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1
  • Intervention Type: Drug
  • Participants: 10
  • Start Date: April 7, 2021
In Utero Enzyme Replacement Therapy (ERT) for Prenatally Diagnosed Lysosomal Storage Disorders (LSDs).
Clinical Trial
  • Status: Not yet recruiting
  • Participants: 150
  • Start Date: April 2021
An Observational National Pediatric Study on Prevalence of Unexplained Splenomegaly
Clinical Trial
  • Status: Active, not recruiting
  • Phase: Phase 1
  • Intervention Type: Drug
  • Participants: 1
  • Start Date: March 17, 2021
A Phase 1b Study of Mivebresib Alone or in Combination With Ruxolitinib or Navitoclax in Subjects With Myelofibrosis
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 4
  • Intervention Type: Drug
  • Participants: 15
  • Start Date: November 20, 2020
A Multicenter, Safety and Efficacy Study of Taliglucerase Alfa in Subjects With Type 3 Gaucher Disease
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1
  • Intervention Type: Drug
  • Participants: 130
  • Start Date: November 11, 2020
A Phase 1b Study Of ABBV-744 Alone Or In Combination With Ruxolitinib Or Navitoclax In Subjects With Myelofibrosis
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1/Phase 2
  • Intervention Type: Other, Drug
  • Participants: 456
  • Start Date: October 2, 2020
Randomised Multi-arm Trial of Ruxolitinib (RUX) and Fostamatinib (FOS) for COVID-19 Pneumonia
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 3
  • Intervention Type: Drug
  • Participants: 230
  • Start Date: September 29, 2020
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Of Navitoclax In Combination With Ruxolitinib Versus Ruxolitinib In Subjects With Myelofibrosis (TRANSFORM-1)
Showing 1-12 of 52